Initial clinic report of TECA-hybrid artificial liver support system to treat patients with acute liver failure

Objective: To assess the efficacy and safety of type TECA hybrid artificial liver support system （HALSS） to treat patients with acute liver failure （ALF）.Methods: The primary hepatocytes were separated from the swine and cultured within the bioreactor of HALSS.First,the plasma of the patients was treated by charcoal sorbent or plasma exchange,then flew through the HALSS for moderate and small molecular weight substances exchanges.Each treatment lasted 6.0～7.0.hours.Observed the changes of physiological and blood biochemical parameters before and after the treatment.Results: Using our modified enzymatic digestion method,the yield of hepatocytes was （1.0～3.0）×10.¹⁰ from perswine with high viability.Type TECA-HALSS treatment resulted in beneficial effects with the levels of plasma NH 3,ALT,AST,TB and DB decreased,the level of PTA ascended.The mentality of the patients turned from coma to consciousness.All patients tolerated the procedure well,the vital signs well stable.No obvious side effects were found during the treatment.Conclusion: Type TECA-HALSS is rapid,safe and efficacious in providing temporary liver support in patients with ALF,so it would hopefully be a new method in the treatment of ALF.